Q2 2026 saw net revenues rise 16% year-over-year and a significant reduction in net loss, with positive adjusted EBITDA. FY 2026 guidance was raised for both revenue and EBITDA, reflecting strong commercial execution and clinical progress.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.